Clinical Guideline / Formulary Document Pharmacy Department Medicines Management Services
|
|
- Jodie Sparks
- 5 years ago
- Views:
Transcription
1 Clinical Guideline / Formulary Document Pharmacy Department Medicines Management Services SUBSTANCE DEPENDENCY For full details of the of the medication discussed in this formulary including side effects, contraindications, drug interactions and monitoring see the Supplementary Product Characteristics available online at: Service users should be offered information on treatments available: acy/patient_information.aspx DUAL DEPENDENCY For persons presenting with 2 or more substances being misused the decision to carry out separate detoxification/stabilisation or concurrently should take into account the person s preference and the severity of dependence for both substances. However detoxification would usually follow the following order: Specialist Advice 1 st Alcohol detoxification 2 nd Benzodiazepine detoxification 3 rd Opiate detoxification Addiction services are available for advice: Kevin White: Alcohol services at Windsor Clinic: Relevant NICE Guidelines Alcohol dependence and harmful alcohol use. (NICE quality standard QS 2011 August 2011) Alcohol-use disorders: diagnosis and clinical management of alcohol-related physical complications (Clinical Guideline 100 June 2010). Alcohol-use disorders: diagnosis, assessment and management of harmful drinking and alcohol dependence (Clinical Guideline 115 February 2011). Naltrexone for the management of opioid dependence. (Technology appraisal guidance 115 January 2007). Nalmefene for reducing alcohol consumption in people with alcohol dependence. (Technology appraisal guidance 325 November 2014) Methadone and buprenorphine for the management of opioid dependence. (Technology appraisal guidance 114 January 2007). Drug misuse: opioid detoxification. (Clinical Guideline 52 July 2007) Psychosis with coexisting substance misuse. (Clinical guidelines 120, evidence update 2012) Substance dependency Next Review: Jan
2 ALCOHOL DEPENDENCE Management of assisted alcohol withdrawal Benzodiazepines should not be administered when the patient is intoxicated and/or breath alcohol content is above 80mg/dl unless there is a history of seizures, in which case it can be given regardless. Benzodiazepines should not be prescribed if the patient is likely to continue drinking. Treatment with benzodiazepines should start when there is clear evidence of alcohol withdrawal symptoms and the dose of benzodiazepines prescribed will depend on the assessment of severity of alcohol dependence (clinical history, number of units per drinking and severity of alcohol withdrawal symptoms). Use formal assessment tools to assess the nature and severity of alcohol misuse, including: AUDIT, SADQ, LDQ, CIWA-ar or APQ. See Appendix 4 of NICE CG115: Laboratory investigations may be necessary in order to correct deficiencies e.g. hypoglycaemia, hypokalaemia and hypomagnesaemia Ensure appropriate hydration. Fixed-dose regimens are recommended for routine use with symptom-triggered dosing reserved for use only with adequate monitoring. Front-loading dosing regimens are not recommended Vitamin supplementation Untreated vitamin deficiencies may result in Wernicke s encephalopathy (WE) that can progress to Korsakoff s psychosis, which may result in permanent cognitive damage. Consider the administration of Pabrinex in patients who are at risk of WE. If patients becomes delirious, IV Pabrinex administered by a doctor may be indicated (liaise with Acute Hospital if necessary). Alcohol withdrawal seizure Review withdrawal drug regimen Risk of alcohol withdrawal seizures may be higher with benzodiazepines with a short half-life such as oxazepam compared with longer half-life such as chlordiazepoxide Delirium Tremens Delirium tremens is a medical emergency that requires urgent treatment Review withdrawal drug regimen Maintenance Treatment Pharmacological treatment should always be adjuvant to counselling. Substance dependency Next Review: Jan
3 Alcohol dependence Management of assisted alcohol withdrawal Chlordiazepoxide Chlordiazepoxide has a slower onset of action than diazepam or lorazepam, and has less potential for abuse. Doses of chlordiazepoxide above BNF limits should not be prescribed without prior discussion with a Consultant or Specialist Registrar. Fixed regimen. Gradually reducing over 7-14 days. Symptom-triggered regime. Service user is monitored on a regular basis and pharmacotherapy is given according to the service user s severity of withdrawal symptoms. Short term use only Other: Relative Cost Notes Diazepam It has similar efficacy to chlordiazepoxide, but has a greater potential for abuse as it has a Liquid faster onset of action. If diazepam is used in the community for acute alcohol detoxification, careful supervision is required. Short term use only Oxazepam Unlicensed use. For people with liver/pancreatic impairment after gastroenterologist advice Lorazepam Liquid Carbamazepine IR Tablets MR Tablets Not recommended: Relative Cost Notes Clomethiazole Other benzodiazepines - has been sought. Short term use only Unlicensed use. For people with liver/pancreatic impairment after gastroenterologist advice has been sought. Short term use only Unlicensed use. Adjunctive prophylactic treatment for patients with a past history of withdrawal seizures or epilepsy of any cause Alcohol combined with clomethiazole, particularly in persons with cirrhosis, can lead to fatal respiratory depression even with short-term use. Substance dependency Next Review: Jan
4 Alcohol dependence Vitamin supplementation Thiamine PO Vitamin Co Strong Other: Relative Cost Notes For people at high risk of developing, or with suspected, Wernicke s encephalopathy. Pabrinex IM High-risk heavy drinkers who are malnourished. Wernicke s encephalopathy suspected or diagnosed. MHRA/CHM advice. Anaphylactic shock may occasionally follow injection (IM lower risk); resuscitation facilities should be available when parenteral thiamine is administered. Alcohol dependence Alcohol withdrawal seizure Diazepam PR Emergency treatment of fits. Other: Relative Cost Notes Lorazepam Tablets Liquid IM Not Recommended: Relative Cost Notes Phenytoin Emergency treatment of fits. Unlicensed use. Adjunctive prophylactic treatment for patients with a past history of withdrawal seizures or epilepsy of any cause. Substance dependency Next Review: Jan
5 Alcohol dependence Delirium Tremens Lorazepam Tablets Liquid IM Other: Relative Cost Notes Unlicensed use Olanzapine PO Unlicensed use. Lowers seizures threshold. Use with caution. Olanzapine IM Haloperidol PO Haloperidol IM Unlicensed use. Lowers seizures threshold. Use with caution. Alcohol dependence Maintenance Treatment Relapse Prevention Acamprosate Initiated by specialist substance misuse teams in combination with psychological interventions. Ensure continuity of prescribing in primary care. Check LFTs & U&Es Other: Relative Cost Notes Disulfiram Initiated by specialist substance misuse teams in combination with psychological interventions. Ensure continuity of prescribing in primary care. Check LFTs & U&Es Naltrexone Initiated by specialist substance misuse teams in combination with psychological interventions. Not to be prescribed to patients on opioids. Ensure continuity of prescribing in primary care. Check LFTs & U&Es Baclofen Unlicensed use. Initiated by specialist substance misuse teams in combination with psychological interventions when there is high levels of anxiety and acamprosate, naltrexone or disulfiram are not appropriate. Antidepressants - Refer to relevant section. Antidepressants should not be routinely used for the treatment of alcohol misuse alone Nalmefene For the reduction of alcohol consumption in adult patients with alcohol dependence who have a high drinking risk level (DRL), without physical withdrawal symptoms, and who do not require immediate detoxification Substance dependency Next Review: Jan
6 Alcohol dependence Symptomatic Relief First Line: Relative Cost Notes Zopiclone Insomnia. Cautious use when co-prescribing of benzodiazepines. Short-term use Prochlorperazine Nausea and vomiting Metoclopramide Nausea and vomiting Chlorphenamine Itching. Check for signs of liver disease. Paracetamol Pain. Caution in severe liver disease Ibuprofen Pain. Caution is asthmatic patients Loperamide Severe diarrhoea Peptac Heartburn Ensure plus Nutritional Supplementation Other: Relative Cost Notes Gaviscon Heartburn Substance dependency Next Review: Jan
7 CLINICAL INSTITUTE WITHDRAWAL ASSESSMENT OF ALCOHOL SCALE, REVISED (CIWA-AR) Patient: Date: Time: Pulse or heart rate, taken for one minute: Blood pressure: NAUSEA AND VOMITING Ask Do you feel sick to your stomach? Have you vomited? Observation: 0 No nausea and no vomiting 1 Mild nausea with no vomiting Intermittent nausea with dry heaves Constant nausea, frequent dry heaves and vomiting TREMOR Arms extended and fingers spread apart Observation: 0 No tremor 1 Not visible, but can be felt fingertip to fingertip Moderate, with patient s arms extended Severe, even with arms not extended PAROXYSMAL SWEATS Observation: 0 No sweat visible 1 Barely perceptible sweating, palms moist Beads of sweat obvious on forehead Drenching sweats ANXIETY Ask Do you feel nervous? Observation: 0 No anxiety, at ease 1 Mild anxious Moderately anxious or guarded, so anxiety in inferred Equivalent to acute panic states as seen in severe delirium or acute schizophrenic reactions TACTILE DISTURBANCES Ask Have you any itching, pins and needles sensations, any burning, any numbness, or do you feel bugs crawling on or under your skin? Observation: 0 None 1 Very mild itching, pins and needles, burning or numbness 2 Mild itching, pins and needles, burning or numbness 3 Moderate itching, pins and needles, burning or numbness 4 Moderately severe hallucinations 5 Severe hallucinations 6 Extremely severe hallucinations 7 Continuous hallucinations AUDITORY DISTURBANCES Ask Are you more aware of sounds around you? Are they harsh? Do they frighten you? Are you hearing anything that is disturbing to you? Are you hearing things you know are not there? Observation: 0 Not present 1 Very mild harshness or ability to frighten 2 Mild harshness or ability to frighten 3 Moderate harshness or ability to frighten 4 Moderately severe hallucinations 5 Severe hallucinations 6 Extremely severe hallucinations 7 Continuous hallucinations VISUAL DISTURBANCES Ask Does the light appear to be too bright? Is its colour different? Does it hurt your eyes? Are you seeing anything that is disturbing to you? Are you seeing things you know are not there? Observations: 0 Not present 1 Very mild sensitivity 2 Mild sensitivity 3 Moderate sensitivity 4 Moderately severe hallucinations 5 Severe hallucinations 6 Extremely severe hallucinations 7 Continuous hallucinations HEADACHE, FULLNESS IN HEAD Ask Does your head feel different? Does it feel like there is a band around your head? Do not rate for dizziness or light-headedness. Otherwise, rate severity: 0 Not present 1 Very mild 2 Mild 3 Moderate 4 Moderately severe 5 Severe 6 Very severe 7 Extremely severe AGITATION Observation: 0 Normal activity 1 Somewhat more than normal activity Moderately fidgety and restless Paces back and forth during most of the interview, or constantly thrashes about ORIENTATION AND CLOUDING OF SENSORIUM Ask What day is this? Where are you? Who am I? Observations: 0 Orientated and can do serial additions 1 Cannot do serial additions or is uncertain about date 2 Disoriented for date by no more than 2 calendar days 3 Disoriented for date by more than 2 calendar days 4 Disoriented for place / or person SCORES: <10- mild withdrawal; moderate withdrawal; >20 severe withdrawal Substance dependency Next Review: Jan
8 Alcohol detoxification regime Please use CLINICAL INSTITUTE WITHDRAWAL ASSESSMENT OF ALCOHOL SCALE REVISED (CIWA-AR) to establish the severity of alcohol dependence and document full history and CIWA score in clinical records. Chlordiazepoxide regime Not to be administered if the patient is intoxicated and/or breath alcohol content is above 80mg/dl unless there is a history of seizures Not recommended in older adults and people with liver impairment. They may need shorter acting benzodiazepines (e.g. oxazepam). Seek advice. Check severity of symptoms using CIWA-Ar score. Mild(< 10 CIWA-AR Score) Chlordiazepoxide 5 mg PRN TDS if necessary Moderate (10 20 CIWA-AR score) DAY 1 DAY 2 DAY 3 DAY 4 DAY mg QDS mg QDS 5-10 mg QDS 5 mg QDS 5 mg BD Severe (>20 CIWA-AR score) (seek specialist advice) Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8 Day 9 Day mg QDS mg QDS mg QDS mg QDS 20 mg QDS 15 mg QDS 10 mg QDS 10 mg TDS 10 mg bd 10 mg nocte Adjuvant medication Thiamine 100mg PO BD/TDS Vitamin B complex Co-strong two tablets PO BD/TDS Chlordiazepoxide 5 mg TDS PRN maximum 15 mg Diazepam 5 mg PR PRN (for seizures) Considering prescribing Pabrinex for: High risk heavy drinker who are malnourished Wernicke s encephalopathy Please ensure that flumazenil and resuscitation facilities are available when following this protocol. Substance dependency Next Review: Jan
9 DRUG MISUSE Opioid dependence Drugs in this section identified by the symbol for Controlled Drugs are subject to prescription requirements, must be indelible, and must be signed by the prescriber, be dated, and specify the prescriber s address. The prescription must always state: o the name and address of the patient; in the case of a preparation, the form (e.g. tablets) and where appropriate the strength of the preparation; o either the total quantity (in both words and figures) of the preparation, or the number (in both words and figures) of dosage units, as appropriate, to be supplied; in any other case, the total quantity (in both words and figures) of the Controlled Drug to be supplied; o the dose. Substitution treatments Opioid substitution treatments should not start until use has been confirmed by positive drug test, the dose has been confirmed by GP or drug clinic, collection has been confirmed by community chemist and opioid withdrawal symptoms are evident. Selection of methadone or buprenorphine should be made on a case-by-case basis taking into consideration patient s preference, but methadone should be prescribed if both drugs are equally suitable. CAUTION: Methadone, even in low doses is a special hazard for children; nondependent adults are also at risk of toxicity; dependent adults are at risk if tolerance is incorrectly assessed during induction. Methadone and Buprenorphine should be prescribed for daily administration, under supervision, for at least the first 3 months. Symptomatic relief Lofexidine is a α2-adrenergic agonist that acts to reduce the noradrenergic hyperactivity seen in opioid withdrawal (e.g. piloerection, sweating, runny nose). Maintenance treatment When prescribing Naltrexone patients should be warned that an attempt to overcome the blockade of opioid receptors by overdosing could result in acute opioid intoxication. Opioid overdoses Opioids in overdose cause coma, respiratory depression and pinpoint pupils. Call an ambulance and start routine emergency lifesaving procedures Other considerations Ultra-rapid detoxification is not recommended Substance dependency Next Review: Jan
10 Opioid dependence Opioid Substitution treatments Methadone Oral 1mg Solution 1mg in 1ml Buprenorphine S/L Tablets Other: Relative Cost Notes Buprenorphine with naloxone S/L Tablets [Suboxone ] Dihydrocodeine Tablets Monitor QT interval in patients with heart or liver disease, electrolyte abnormalities, concomitant treatment with drugs that can prolong QT interval and patients requiring more than 100 mg daily. Dose should take into consideration drug interactions. Sugar Free (SF) should be considered for diabetics and to avoid tooth decay in long-term users Administer the first dose when the patient is exhibiting signs of withdrawal or at least 6 12 hours after the last use of heroin (or other short-acting opioid), or hours after the last dose of methadone. In patients receiving methadone, dose of methadone should be reduced to max. 30 mg daily before starting buprenorphine. Only by specialist substance misuse teams. See Buprenorphine advice. Prevents/Reduces the liability for abuse, if crushed and intravenously injected, withdrawal effects occur. Unlicensed use. Only by specialist substance misuse teams. Methadone Tablets Unlicensed use. Only by specialist substance misuse teams. They can be crushed and inappropriately injected, and should only be prescribed under specialist supervision Methadone Conc mixture Only by specialist substance misuse teams. High risk of overdose and inappropriate injection Methadone injection Under specialist supervision for a person with a long history of injecting heroin who has gained no benefit from using oral methadone Diamorphine Injection - Only medical practitioners who hold a special license issued by the Home Secretary may prescribe, administer, or supply diamorphine Substance dependency Next Review: Jan
11 Opioid dependence Symptomatic relief Lofexidine Monitor pulse and blood pressure. Withdraw gradually over 2-4 days (or longer) to minimise risk of rebound hypertension and associated symptoms. It may be use in place of opioid substitution treatments Zopiclone Insomnia.. Cautious use when co-prescribing of benzodiazepines. Short-tem use Prochlorperazine Nausea and vomiting Metoclopramide Nausea and vomiting Chlorphenamine Itching. Check for signs of liver disease. Paracetamol Pain. Caution in severe liver disease Ibuprofen Pain. Caution in asthmatic patients Loperamide Severe diarrhoea Peptac Heartburn Ensure plus Nutritional Supplementation Other: Relative Cost Notes Gaviscon Heartburn Nefopam Pain Antipsychotics - Refer to relevant section. Unlicensed. Antidepressants - Refer to relevant section. Unlicensed. Substance dependency Next Review: Jan
12 Opioid dependence Abstinence Maintenance Treatment Naltrexone Only by specialist substance misuse teams in combination with counselling. Avoid concomitant use of opioids. Administer first dose 7-10 days after last opioids consumption Opioid dependence Opioid overdose Naloxone Contact Emergency Services. Short duration, repeated administration may be needed. See NHS England on risks of inappropriate doses of naloxone. Substance dependency Next Review: Jan
13 METHADONE PRESCRIBING FOR OPIOID DEPENDENCE Opiate replacement therapy should only be prescribed if a diagnosis of opiate dependence is made. Before prescribing methadone, opioid use must be confirmed by positive urine results for opioids and objective signs of withdrawal (see table). GP, community pharmacy, keyworker or prison medical officer should be contacted when relevant and documented in clinical notes. Opioid withdrawal symptoms Objective opioid withdrawal scales Symptoms Absent/normal Mild-Moderate Severe Lacrimation Absent Eyes watery Eyes streaming/wiping eyes Rhinorrhoea Absent Sniffing Profuse secretion (wiping nose) Agitation Absent Fidgeting Can t remain seated Perspiration Absent Clammy skin Beads of sweat Piloerection Absent Barely palpable Readily palpable, visible hairs standing up Pulse rate (BPM) <80 >80 but <100 >100 Vomiting Absent Absent Present Shivering Absent Absent Present Yawning/10 min < or more Dilated pupils Normal <4mm Dilated 4-6 mm Widely dilated >6mm Subjective opioid withdrawal symptoms can include: nausea; stomach cramps, muscular tension; muscle spasms/twitching; aches and paints; insomnia. Opioid withdrawal is not a life-threatening condition, opioid toxicity is. Do not administer methadone if the patient is drowsy or asleep Methadone prescribing If methadone dose is confirmed and clinically appropriate it is recommended that the total daily dose is prescribed as two split doses for 3 days. Dose can be prescribed as a single dose thereafter. Doses above 40mg should be agreed with the consultant. It is important to remember that several missed doses may mean a loss of tolerance to opioids. Three more days missed consecutively should lead to a dose review. If methadone dose is not confirmed Prescribe a single dose of methadone 10mg on the "once only" part of the prescription chart. A second dose of methadone 10mg may be prescribed and given no sooner than four hours after the first dose. The patient should not receive more than 20mg of methadone in the first 12 hours and no more than 40mg in 24hours Where doses need to be increased during the first seven days, the increment should be no more than 5 mg to 10mg on one day. In any event, a total weekly increase should not usually exceed 30mg above the starting day s dose. Substance dependency Next Review: Jan
14 BENZODIAZEPINE DEPENDENCE Management of assisted benzodiazepine withdrawal Withdrawal of a benzodiazepine should be gradual because abrupt discontinuation may cause confusion, toxic psychosis, convulsions, or a condition resembling delirium tremens. Benzodiazepine withdrawal may be undertaken with or without switching to diazepam but the switch is recommended for people: o with previous difficult withdrawal attempts o on short-acting potent benzodiazepines such as alprazolam and lorazepam o on preparations that do not easily allow for small reductions in dose (that is alprazolam, flurazepam, loprazolam and lormetazepam) Approximate equivalent doses of diazepam 5mg o Chlordiazepoxide 15mg o Loprazolam 0.5-1mg o Lorazepam 0.5mg-1mg o Lormetazepam 0.5-1mg o Nitrazepam 5 mg o Oxazepam 15mg o Temazepam 10mg Steps may be adjusted according to initial dose and duration of treatment and can range from diazepam 500micrograms (one quarter of a 2mg tablet) to 2.5mg. Emergency treatment of overdoses Benzodiazepine overdose cause drowsiness, ataxia, dysarthria, nystagmus, and occasionally respiratory depression and coma. Substance dependency Next Review: Jan
15 Benzodiazepine dependence Substitution treatments First Line: Price Band Notes Diazepam Diazepam is preferred because it possesses a long half-life and is available in a variety of Tablets Liquid strengths and formulations. Second Line: Price Band Notes Nitrazepam For nitrazepam dependent patients. Temazepam For temazepam dependent patients. Benzodiazepine dependence Symptomatic relief Other: Price Band Notes Propranonol IR Tablets Less suitable for prescribing. For severe, physical symptoms of anxiety (such as palpitations, tremor and sweating) only if other measures fail. MR Tablets Liquid Antidepressants - When depression or panic disorder coexist or emerge during drug withdrawal. See relevant section. Benzodiazepine dependence Emergency treatment of overdoses First Line Price Band Notes Flumazenil Contact Emergency Services. In in-patients services may be administered IV by doctors only. Other Substance dependency Next Review: Jan
16 REFERENCES 1. BAP updated evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity (2012) 2. BNF 68 (2014) British National Formulary. 68nd ed. London: British Medical Association and Royal Pharmaceutical Society of Great Britain. 3. CHM (2006) Risk of QT interval prolongation with methadone. Current Problems in Pharmacovigilance DH (2007). Drug misuse and dependence: UK guidelines on clinical management. (September 2007) 5. Maudsley (2012). Taylor D, Paton C and Kapur S. The South London and Maudsley NHS Trust 2012 Prescribing Guidelines 11th Edition. 6. MHRA. Medicines information: product details for Adepend 50mg tablets (2013) NICE (2010). Alcohol-use disorders: diagnosis and clinical management of alcohol-related physical complications (Clinical Guideline 100 June 2010). 8. NICE (2011) Alcohol-use disorders: diagnosis, assessment and management of harmful drinking and alcohol dependence (Clinical Guideline 115 February 2011). 9. NICE (2007a) Naltrexone for the management of opioid dependence. (Technology appraisal guidance 115 January 2007). 10. NICE (2007b) Methadone and buprenorphine for the management of opioid dependence. (Technology appraisal guidance 114 January 2007). 11. NICE (2007d) Drug misuse: opioid detoxification. (Clinical Guideline 52 July 2007) 12. NTA (2006). National Treatment Agency for Substance Misuse. Review of the effectiveness of treatment for alcohol problems (November 2006) 13. NTA (2006a) Treating drug misuse problems: evidence of effectiveness. 14. NICE (2011). Psychosis with co-existing substance misuse. 15. NICE (2014). Nalmefene for reducing alcohol consumption in people with alcohol dependence (Technology appraisal 325 November 2014) 16. Pan Mersey area prescribing committee. Prescribing policy statement (2013) on Nalmefene 17. Psychotropic drug directory (2014). Bazire S. Lloyd-Reinhold Communications LLP 18. RCGP (2011) Guidance for the use of substitute prescribing in the treatment of opioid dependence in primary care. 19. SIGN (2003). Scottish Intercollegiate Guidelines Network. The management of harmful drinking and alcohol dependence in primary care (September 2003) 20. Sweetman, S.C. (Ed.) (2011) Martindale: the complete drug reference. 38th ed. London: Pharmaceutical Press. 21. Various Summaries of Products Characteristics. Electronic Medicines Compendium; Substance dependency Next Review: Jan
Stabilization Algorithm
VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders Stabilization Algorithm Stabilization Pocket Card 1 Patient and Time Information Clinical Institute Withdrawal Assessment
More informationAlcohol withdrawal. Clinical features
Alcohol withdrawal Clinical features Severity increase with amount consumed; uncommon with < drinks per day. Predictable pattern: patients with previous withdrawal seizures are at high risk for recurrence.
More informationALCOHOL WITHDRAWAL GUIDELINES
ALCOHOL WITHDRAWAL GUIDELINES Policy author Accountable Executive Lead Approving body Policy reference Dr M Lewis, Gastroenterologist; Professor J A Vale, Clinical Toxicologist; Dr D A Robertson, Alcohol
More informationAssessment Main title and management of alcohol dependence and withdrawal in the acute hospital: concise guidance
CONCISE GUIDANCE Clinical Medicine 01, Vol 1, No : 71 Assessment Main title and management of alcohol dependence and withdrawal in the acute hospital: concise guidance Author head name Stephen Stewart
More informationAPPENDIX 7 CLINICAL INSTITUTE NARCOTIC ASSESSMENT (CINA) SCALE FOR WITHDRAWAL SYMPTOMS
APPENDIX 7 CLINICAL INSTITUTE NARCOTIC ASSESSMENT (CINA) SCALE FOR WITHDRAWAL SYMPTOMS The Clinical Institute Narcotic Assessment (CINA) Scale measures 11 signs and symptoms commonly seen in patients during
More informationLead for Gastroenterology Lee Dodge Alcohol Liaison 03/03/2015. Clive Gibson Safeguarding Adults Lead Nurse 03/03/2015
Acute Alcohol Withdrawal Management for Adult Inpatients Type: Clinical Guideline Register No: 1409 Status: Public on ratification Developed in response to: Best Practice Contributes to CQC Outcome number:
More informationAlcohol Withdrawal Guidelines
SH CP 197 Alcohol Withdrawal Guidelines Summary: Keywords: Target Audience: Identification, assessment and management of alcohol dependence and harmful alcohol use in people presenting for assessment or
More informationPharmacological Therapy Policy Practice Guidance Note Management of Acute Alcohol Withdrawal in Adults (Over 18) - V01. Planned review: December 2017
Pharmacological Therapy Policy Practice Guidance Note Management of Acute Alcohol Withdrawal in Adults (Over 18) - V01 V01 issued: Issue 1- Dec 14 Issue 2 April 17 Planned review: December 2017 PPT-PGN
More informationSECTION 10: MANAGEMENT OF ALCOHOL, OPIOID AND BENZODIAZEPINE DEPENDENCE. Formulary and Prescribing Guidelines
SECTION 10: MANAGEMENT OF ALCOHOL, OPIOID AND BENZODIAZEPINE DEPENDENCE Formulary and Prescribing Guidelines 10.1 Introduction This document covers the safe prescribing and management for service users
More informationAlcohol Detoxification (Inpatient) Prescribing Guidelines
Alcohol Detoxification (Inpatient) Prescribing Guidelines Author: Sponsor/Executive: Responsible committee: Consultation & Approval: (Committee/Groups which signed off the procedure, including date) This
More informationPolicy on Pharmacological Therapies Practice Guidance Note Reducing Dosing Errors with Opioid Medicines V04
Policy on Pharmacological Therapies Practice Guidance Note Reducing Dosing Errors with Opioid Medicines V04 Date issued Issue 1 Nov 2018 Planned review Nov 2021 PPT-PGN 18 part of NTW(C)38 Pharmaceutical
More informationPOLICY DOCUMENT. CG/pain management in opioid dependency/03/15. Associate Director of Pharmacy
POLICY DOCUMENT Document Title Reference Number PRESCRIBING FOR PAIN MANAGEMENT IN OPIOID DEPENDENT CLIENTS CG/pain management in opioid dependency/03/15 Policy Type Clinical Guideline Electronic File/Location
More informationSHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR ALCOHOL DEPENDENCE INDICATION
SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR ALCOHOL DEPENDENCE INDICATION Naltrexone is used as part of a comprehensive programme of treatment against alcoholism to reduce the
More informationPharmacological Therapy Policy Practice Guidance Note Management of Acute Alcohol Withdrawal in Adults (Over 18) - V02. Planned review: Dec 2020
Pharmacological Therapy Policy Practice Guidance Note Management of Acute Alcohol Withdrawal in Adults (Over 18) - V02 Issue No: Issue 1- Dec 17 Planned review: Dec 2020 PPT-PGN 22 Part of NTW(C)38 Pharmacological
More informationPrescribing Framework for Naltrexone in Relapse Prevention (Opioid Dependence)
Hull & East Riding Prescribing Committee Prescribing Framework for Naltrexone in Relapse Prevention (Opioid Dependence) Patients Name: Unit Number: Patients Address:.. G.P s Name:.. Communication We agree
More informationC AT E G O R Y I I I COMMUNICATION, TREATMENT & PREVENTION INTERVENTIONS PHARMACOLOGY OF ADDICTIONS
C AT E G O R Y I I I COMMUNICATION, TREATMENT & PREVENTION INTERVENTIONS PHARMACOLOGY OF ADDICTIONS 1.0 Introduction Medications are used in the treatment of drug, alcohol and nicotine dependence to manage
More informationConsulted With: Post/Committee/Group: Date: John Crome Drug and Alcohol Liaison Emergency Care
THE MANAGEMENT OF OPIOID WITHDRAWAL IN ADULT PATIENTS Type: Clinical Guideline Register No: 18007 Status: Public on ratification Developed in response to: Contributes to CQC Outcome number: 12 Best practice
More informationAlcohol withdrawal including the Symptom triggered CIWA score Management
Alcohol withdrawal including the Symptom triggered CIWA score Management Classification: Policy Lead Author: Ruth Brown Alcohol specialist Nurse Additional author(s): Hailey Pennington Authors Division:
More informationSHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE
SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE INDICATION Naltrexone is a pure opiate antagonist licensed as an adjunctive prophylactic therapy in the maintenance
More informationFormulary and Clinical Guideline Document Pharmacy Department Medicines Management Services
Formulary and Clinical Guideline Document Pharmacy Department Medicines Management Services VIOLENCE, AGGRESSION OR SEVERE BEHAVIOURAL DISTURBANCE Introduction During an acute episode or illness, some
More informationGuidance For The Use Of Lofexidine In The Symptomatic Management Of Opioid Withdrawal By Clinicians Working Within NHS Grampian. Consultation Group:
NHS...Ness Grampian Guidance For The Use Of Lofexidine In The Symptomatic Management Of Opioid Withdrawal By Clinicians Working Within NHS Grampian Co-ordinators: Specialist Pharmacists in Substance Misuse
More informationNHS Fife Guidance for the Identification, Assessment and Management of Harmful Drinking and Alcohol Dependence
NHS Fife Guidance for the Identification, Assessment and Management of Harmful Drinking and Alcohol Dependence Staff working in services provided and funded by the NHS who care for people who potentially
More informationTitle Alcohol Withdrawal Management Guidelines
Document Control Title Alcohol Withdrawal Management Guidelines Author Directorate Date Version Issued 0.1 Dec 2009 0.2 Mar 2010 0.3 Nov 2010 Status Draft 0.4 Sep 2015 1.0 Jan 2016 2.0 Nov Final 2018 Main
More informationCMBHS Clinical Management of Behavioral Health Services
Client: CMBHS Clinical Management of Behavioral Health Services Detoxification Assessment Assessment Information (te: All are Required fields) Assessment Number Assessment Date Assessment Type Contact
More informationWithdrawal.
Withdrawal Shamim Nejad, MD Director, Adult Burns & Trauma Psychiatry Division of Psychiatry and Medicine Medical Director, Addiction Consultation Team MGH Center for Addiction Medicine Massachusetts General
More informationGuidance For The Use Of Naltrexone In The Maintenance Of Abstinence in Formerly Opioid Dependent Adults By Clinicians Working Within NHS Grampian
Title: Identifier: Guidance For The Use Of Naltrexone In The Maintenance Of Abstinence in Formerly Opioid Dependent Adults By Clinicians Working Within NHS Grampian NHSG/Guide/NHSG_NaltexMA_885 Replaces:
More informationNorthern Ireland Alcohol Use Disorders Care Pathway. management in the acute hospital setting
Northern Ireland Alcohol Use Disorders Care Pathway management in the acute hospital setting Main Content 1. Introduction 2 2. Alcohol Withdrawal Syndrome 3 2.1. Delirium tremens 3 2.2. Seizures 4 2.3.
More informationGuidelines for the In-Patient Management of Alcohol Withdrawal at Frimley Park Hospital NHS Foundation Trust
Guidelines for the In-Patient Management of Alcohol Withdrawal at Frimley Park Hospital NHS Foundation Trust Authors: Dr Aftab Ala, Consultant Gastroenterologist & Hepatologist Dr Tasneem Pirani, ST4 in
More informationTreatment of Alcohol and Opiate Withdrawal
Objectives Treatment of Alcohol and Opiate Withdrawal Renee Striker, Pharm.D., BCPS, BCPP Pharmacy Clinical Specialist Huron Hospital East Cleveland, Ohio Outline the diagnostic criteria for substance
More informationPrescribing for substance misuse: alcohol detoxification. Clinical background
Prescribing for substance misuse: alcohol detoxification POMH-UK Quality Improvement Programme. Topic 14a: baseline Clinical background 1 2014 The Royal College of Psychiatrists. For further information
More informationSUBOXONE (buprenorphine and naloxone) sublingual film (CIII) IMPORTANT SAFETY INFORMATION
SUBOXONE (buprenorphine and naloxone) sublingual film (CIII) IMPORTANT SAFETY INFORMATION What is the most important information I should know about SUBOXONE Film? Keep SUBOXONE Film in a secure place
More informationPrescribing Framework for Naltrexone in Alcohol Relapse Prevention
Prescribing Framework for Naltrexone in Alcohol Relapse Prevention Patients Name:.. NHS Number: Patients Address:... (Use addressograph sticker) GP s Name:... Communication We agree to treat this patient
More informationBuprenorphine treatment
South London and Maudsley NHS Foundation Trust Buprenorphine treatment Information for service users Page Buprenorphine treatment What is buprenorphine? Buprenorphine (trade name Subutex ) is an opioid
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationMEDICALLY ASSISTED COMMUNITY ALCOHOL WITHDRAWAL GUIDELINES SEPTEMBER 2015
MEDICALLY ASSISTED COMMUNITY ALCOHOL WITHDRAWAL GUIDELINES SEPTEMBER 2015 This policy supersedes all previous policies for medically assisted community alcohol withdrawal Policy title Guidelines for medically
More informationBenzodiazepines and Hypnotics
Benzodiazepines and Hypnotics Full Title of Guideline: Author (include email and role): Division & Speciality: Scope (Target audience, state if Trust wide): Review date (when this version goes out of date):
More informationMANAGEMENT AND DETOXIFICATION FOR GAMMA- HYDROXYBUTYRATE (GHB) AND GAMMA-BUTARYL LACTONE (GBL) GUIDELINES SEPTEMBER 2017
MANAGEMENT AND DETOXIFICATION FOR GAMMA- HYDROXYBUTYRATE (GHB) AND GAMMA-BUTARYL LACTONE (GBL) GUIDELINES SEPTEMBER 2017 Policy title Management and Detoxification for GHB and GBL Policy PHA61 reference
More informationMERSEY CARE NHS TRUST HOW WE MANAGE MEDICINES. MM11 - High-Dose Antipsychotic Use Guidelines (local guideline) KEY ISSUES
MERSEY CARE NHS TRUST HOW WE MANAGE MEDICINES MM11 - High-Dose Antipsychotic Use Guidelines (local guideline) Medicines Management Services aim to ensure that (i) Service users receive their medicines
More informationROLE OF HEALTH CARE PROVIDERS IN THE MANAGEMENT OF ALCOHOL AND DRUG USE RELATED PROBLEMS
ROLE OF HEALTH CARE PROVIDERS IN THE MANAGEMENT OF ALCOHOL AND DRUG USE RELATED PROBLEMS Dr. Anita Rao? ASK SCREEN Refer HELP T T Ranganathan Clinical Research Foundation TTK Hospital IV Main Road, Indira
More informationNorthern Ireland Alcohol Use Disorders Care Pathway. management in the acute hospital setting
Northern Ireland Alcohol Use Disorders Care Pathway management in the acute hospital setting Main Content 1. Introduction 2 2. Alcohol Withdrawal Syndrome 3 2.1. Delirium tremens 3 2.2. Seizures 4 2.3.
More informationINPATIENT ALCOHOL WITHDRAWAL PRESCRIBING GUIDELINES MAY 2018
INPATIENT ALCOHOL WITHDRAWAL PRESCRIBING GUIDELINES MAY 2018 Policy title Inpatient alcohol withdrawal Prescribing Guidelines Policy PHA28B reference Policy category Clinical Relevant to Trust-wide any
More informationBrief guide: substance misuse services detoxification or withdrawal from drugs or alcohol
. Brief guide: substance misuse services detoxification or withdrawal from drugs or alcohol Context Detoxification or withdrawal is a key stage in achieving abstinence for people who are dependent on drugs
More informationALCOHOL ASSESSMENT AND DETOXIFICATION POLICY FOR INPATIENTS
ALCOHOL ASSESSMENT AND DETOXIFICATION POLICY FOR INPATIENTS Version: 4 Date issued: August 2017 Review date: August 2020 Applies to: All staff working within Trust Inpatient settings This document is available
More informationSHARED CARE GUIDELINE
SHARED CARE GUIDELINE Methylphenidate in the treatment of Attention Deficit Hyperactivity Disorder in Children, Young People and Adults Implementation Date: June 2015 Review Date: June 2017 This guidance
More informationGUIDELINES FOR ALCOHOL DETOXIFICATION AT HMP BEDFORD
GUIDELINES FOR ALCOHOL DETOXIFICATION AT HMP BEDFORD Policy Details NHFT document reference MMG027/HMP Version 1 Date Ratified May 2017 Ratified by HMP Bedford Drugs and Therapeutics Committee Implementation
More informationSubstitution Therapy for Opioid Use Disorder The Role of Suboxone
Substitution Therapy for Opioid Use Disorder The Role of Suboxone Methadone/Buprenorphine 101 Workshop, December 10, 2016 Leslie Lappalainen, MD, CCFP, dip ABAM Prepared by Mandy Manak, MD, ABAM, CCSAM
More informationGuidance for naltrexone prescribing
Document level: Drug Alcohol (Trustwide) Code: DA7 Issue number: 2 Guidance for naltrexone prescribing Lead executive Authors details Type of document Target audience Document purpose Lead Clinical Director
More informationOpioid rotation or switching may be considered if a patient obtains pain relief with one opioid and is suffering severe adverse effects.
Dose equivalence and switching between opioids Key Messages Switching from one opioid to another should only be recommended or supervised by a healthcare practitioner with adequate competence and sufficient
More informationGuidelines for Community Detoxification using Buprenorphine.
Subject Title NHS Fife Community Health Partnerships Addiction Services Guidelines for Community Detoxification using Buprenorphine. Intranet Procedure No A3 Author Dr A Baldacchino Copy No 3 Reviewer
More informationMEDICATION GUIDE SUBOXONE (Sub OX own) (buprenorphine and naloxone) Sublingual Tablets (CIII)
MEDICATION GUIDE SUBOXONE (Sub OX own) (buprenorphine and naloxone) Sublingual Tablets (CIII) IMPORTANT: Keep SUBOXONE in a secure place away from children. Accidental use by a child is a medical emergency
More informationClinical Guidelines and Procedures for the Use of Naltrexone in the Management of Opioid Dependence Abbreviated Version
Clinical Guidelines and Procedures for the Use of Naltrexone in the Management of Opioid Dependence Abbreviated Version Clinical Guidelines and Procedures for the Use of Naltrexone in the Management of
More informationLorraine Wilson, 74 years of age, is admitted. Alcohol Withdrawal. During Hospitalization. Early recognition and consistent intervention are critical.
1.9 h o u r s Continuing Education Withdrawal During Hospitalization Early recognition and consistent intervention are critical. Overview: For a chronic drinker, sudden alcohol withdrawal because of an
More informationAcute Alcohol Withdrawal Protocol
Acute Alcohol Withdrawal Protocol Controlled document This document is uncontrolled when downloaded or printed Reference number Version 1 Author WHHT: C268 Dr Mohamed Shariff Date ratified August 2014
More informationCritical Care Pharmacological Management of Delirium
Critical Care Pharmacological Management of Delirium Policy Title: in the Critical Care Unit Executive Summary: This policy provides guidance Pharmacological Management of delirium in the Critical Care
More informationOpioid dependence: Detoxification
Opioid dependence: Detoxification What is detoxification? A. Process of removal of toxins from the body? B. Admitting a drug dependent person in a hospital and giving him nutrition? C. Stopping drug use
More informationSoma (carisoprodol), Soma Compound (carisoprodol and aspirin), Soma Compound w/ Codeine (carisoprodol and aspirin and codeine)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.75.07 Subject: Page: 1 of 7 Last Review Date: September 15, 2016 Description (carisoprodol), Compound
More informationPrescribing for substance misuse: alcohol detoxification
Prescribing for substance misuse: alcohol POMH-UK Quality Improvement Programme. Topic 14b (re-audit) Prepared by the Prescribing Observatory for Mental Health-UK for Non-participating Trusts Published
More informationSoma (carisoprodol), Soma Compound (carisoprodol and aspirin), Soma Compound w/ Codeine (carisoprodol and aspirin and codeine)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.75.07 Subject: Soma Page: 1 of 7 Last Review Date: September 15, 2017 Soma Description Soma (carisoprodol),
More informationMethodist Hospital Alcohol Withdrawal Suggested Guidelines
Methodist Hospital Alcohol Withdrawal Suggested Guidelines S. Prizada Sattar, MD Teri L Gabel, Pharm.D.,BCPP Sidney Kauzlarich, MD Subhash Bhatia, MD Mitzi Bollinger, RN S. Prizada Sattar, MD 6-20-3 Rationale
More informationBACKGROUND Measuring renal function :
A GUIDE TO USE OF COMMON PALLIATIVE CARE DRUGS IN RENAL IMPAIRMENT These guidelines bring together information and recommendations from the Palliative Care formulary (PCF5 ) BACKGROUND Measuring renal
More informationGuidance for community alcohol detoxification in clients with complex needs
Document level: Clinical Service Unit (CSU) Code: DA3 Issue number: 1 Guidance for community alcohol detoxification in clients with complex needs Lead executive Medical Director Author and contact number
More informationGREATER MANCHESTER INTERFACE PRESCRIBING GROUP
GREATER MANCHESTER INTERFACE PRESCRIBING GROUP On behalf of the GREATER MANCHESTER MEDICINES MANAGEMENT GROUP SHARED CARE GUIDELINE FOR THE PRESCRIBING OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)
More informationTalking with your doctor
SUBOXONE (buprenorphine and naloxone) Sublingual Film (CIII) Talking with your doctor Opioid dependence can be treated. Talking with your healthcare team keeps them aware of your situation so they may
More informationCritical Care Pharmacological Management of Delirium
Critical Care Pharmacological Management of Delirium Policy Title: in the Critical Care Unit Executive Summary: This policy provides guidance Pharmacological Management of delirium in the Critical Care
More informationGuidance For The Detoxification Of Alcohol Dependent Patients In Community Or Outpatient Settings
Guidance For The Detoxification Of Alcohol Dependent Patients In Community Or Outpatient Settings Co-ordinators: Fiona Raeburn, Specialist Pharmacist in Substance Misuse Reviewer: Dr Seonaid Anderson,
More informationClinical Policy: Lofexidine (Lucemyra) Reference Number: ERX.NPA.88 Effective Date:
Clinical Policy: (Lucemyra) Reference Number: ERX.NPA.88 Effective Date: 07.31.18 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationYou will be prescribed a preparation in the strength of 1mg/1ml. Methadone, like heroin can also cause a physical dependence.
METHADONE LEAFLET: What is Methadone? Methadone is a synthetic drug, used in the treatment of people who have a physical dependence to opiates, thereby preventing the onset of opiate withdrawal symptoms
More informationNeuropathic Pain Treatment Guidelines
Neuropathic Pain Treatment Guidelines Background Pain is an unpleasant sensory and emotional experience that can have a significant impact on a person s quality of life, general health, psychological health,
More informationGuideline for GP s in primary care for safe prescribing of acamprosate in Sheffield
Guideline for GP s in primary care for safe prescribing of acamprosate in Sheffield Authors Dr O Lagundoye-Consultant Psychiatrist/Clinical Director MBBS MRCPsych Substance Misuse Service, Sheffield Health
More informationGuidelines on Medical Treatments for Substance Misuse. May Tayside Substance Misuse Service
Guidelines on Medical Treatments for Substance Misuse May 2015 Tayside Substance Misuse Service Introduction Tayside Substance Misuse Service (TSMS) TSMS comprises the specialist NHS elements of the comprehensive
More informationPharmacological Management of Substance Misuse. Prescribing Guideline
Pharmacological Management of Substance Misuse in Community Prescribing Guideline Ref No: 1893 Version 4 Date: 25 October 2018 in Community Prescribing Guideline Page 1 of 15 Pharmacological Management
More informationManagement of Alcohol Dependence
STANDARD TREATMENT GUIDELINES Management of Alcohol Dependence Quick Reference Guide February 2016 Ministry of Health & Family Welfare Government of India 1 Table of Contents Objectives-... 3 Diagnosis...
More informationControlled Document Number: Version Number: 1. Controlled Document Sponsor: Controlled Document Lead (Author): On: July Review Date: July 2020
Guidelines for the Use of Naloxone in Palliative Care in Adult Patients CONTROLLED DOCUMENT CATEGORY: CLASSIFICATION: Controlled Document Number: Version Number: 1 Controlled Document Sponsor: Controlled
More informationSCENARIOS IN SUBSTANCE MISUSE. By Dr Gideon Felton Consultant Psychiatrist and Clinical Lead
SCENARIOS IN SUBSTANCE MISUSE By Dr Gideon Felton Consultant Psychiatrist and Clinical Lead ALCOHOL SCENARIOS DON T PRESCRIBE LIBRIUM AS YOU ARE CONTRIBUTING TO A SECOND ADDICTION WITHOUT TREATING THE
More informationA prisoners guide to buprenorphine
A prisoners guide to buprenorphine 2 The Opium poppy In the land of far, far away the opium poppy grows. The seed pods of this poppy are scratched until they drip with a sticky resin called opium. Raw
More informationWhat is pregabalin? Pregabalin tablets. Pregabalin misuse. National Drug Treatment Centre Research. Administration
What is pregabalin? Pregabalin is a prescription drug used to manage a number of long-term conditions, including epilepsy, neuropathic pain and generalised anxiety disorder. Similar to benzodiazepines,
More informationPain Management for Adult sickle cell disease patients: Information for patients, relatives and carers
Pain Management for Adult sickle cell disease patients: Information for patients, relatives and carers Why you should read this leaflet This leaflet will give you the information necessary to manage your
More informationClinical guideline Published: 23 February 2011 nice.org.uk/guidance/cg115
Alcohol-use disorders: diagnosis, assessment and management of harmful drinking and alcohol dependence Clinical guideline Published: 23 February 2011 nice.org.uk/guidance/cg115 NICE 2018. All rights reserved.
More informationM0BCore Safety Profile. Active substance: Bromazepam Pharmaceutical form(s)/strength: Tablets 6 mg FR/H/PSUR/0066/001 Date of FAR:
M0BCore Safety Profile Active substance: Bromazepam Pharmaceutical form(s)/strength: Tablets 6 mg P-RMS: FR/H/PSUR/0066/001 Date of FAR: 26.11.2013 4.3 Contraindications Bromazepam must not be administered
More informationMedications in the Treatment of Opioid Use Disorder: Methadone and Buprenorphine What Really Are They?
Medications in the Treatment of Opioid Use Disorder: Methadone and Buprenorphine What Really Are They? Yngvild Olsen, MD, MPH Cecil County Board of Health Workgroup Meeting Elkton, MD October 8, 2013 Objectives
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Drug Misuse: opiate detoxification of drug misusers in the community, hospital and prison. 1.1 Short title Drug misuse detoxification
More informationPROCEDURE REF NO SABP/EXECUTIVE BOARD/0017
PROCEDURE REF NO SABP/EXECUTIVE BOARD/0017 NAME OF GUIDELINE REASON FOR GUIDELINE WHAT THE GUIDELINE WILL ACHIEVE? WHO NEEDS TO KNOW ABOUT IT? Medicines Guideline: Hypnotic Medication Compliance with NICE
More informationMMG003 GUIDELINES FOR THE USE OF HYPNOTICS FOR THE TREATMENT OF INSOMNIA
MMG003 GUIDELINES FOR THE USE OF HYPNOTICS FOR THE TREATMENT OF INSOMNIA Page 1 of 11 Table of Contents Why we need this Guideline... 3 What the Policy is trying to do... 3 Which stakeholders have been
More informationLONG TERM PHARMACOTHERAPY OF OPIOID DEPENDENCE
LONG TERM PHARMACOTHERAPY OF OPIOID DEPENDENCE DR. SHILPA ADARKAR ASSOCIATE PROFESSOR DEPARTMENT OF PSYCHIATRY & DRUG DEADDICTION CENTRE OF EXCELLENCE SETH GSMC & KEMH LONG TERM OPTIONS FULL AGONIST PARTIAL
More informationAlcohol Interventions: NICE guidelines and beyond. Professor Colin Drummond
Alcohol Interventions: NICE guidelines and beyond Professor Colin Drummond What this presentation covers Background Scope Methodology What is new? Implications for practice Implementation International
More informationAnalgesia for Patients with Substance Abuse Disorders. Lisa Jennings CN November 2015
Analgesia for Patients with Substance Abuse Disorders Lisa Jennings CN November 2015 Definitions n Addiction: A pattern of drug use characterised by aberrant drug-taking behaviours & the compulsive use
More informationSummary of Recommendations...3. PEG: A Three-Item Scale Assessing Pain (Appendix A) Chronic Pain Flow Sheet Acute Pain Flow Sheet...
Table of Contents Summary of Recommendations....3 PEG: A Three-Item Scale Assessing Pain (Appendix A)...12 Chronic Pain Flow Sheet...13 Acute Pain Flow Sheet...14 Pocket Guide: Tapering Opioids for Chronic
More informationMid Essex Locality Guideline for Management of Adult Acute and Chronic Non-Cancer Pain in Primary care
Guideline for Management of Adult Acute and Chronic Non-Cancer Pain in Primary care If possible patients should be assessed using a simple visual analogue scale VAS to determine the most appropriate stage
More informationClinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT)
Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT) What has changed? Effective January 16, 2018, Coordinated Care will change the requirement for form HCA 13-333 Medication
More informationBenzodiazepines Information for GPs
Drug and Alcohol Services South Australia Benzodiazepines Information for GPs This information is designed to assist doctors in the management of patients ceasing benzodiazepine use, and is to be read
More informationOpioid Agonists. Natural derivatives of opium poppy - Opium - Morphine - Codeine
Natural derivatives of opium poppy - Opium - Morphine - Codeine Opioid Agonists Semi synthetics: Derived from chemicals in opium -Diacetylmorphine Heroin - Hydromorphone Synthetics - Oxycodone Propoxyphene
More informationPPT-PGN-26 Part of NTW(C)38-Pharmacological therapies
Pharmacological therapies - Practice Guidance Note Guidance for the in-patient use of opiate substitution therapy.v01 Date Issued Issue 1 Jun 2018 Planned Review Jun 2021 PPT-PGN-26 Part of NTW(C)38-Pharmacological
More informationClinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT)
Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT) For Apple Health clients served Fee-for-Service and through contracted Medicaid Managed Care Organizations Updated January
More informationDate: 22nd March 2018 Our Ref: FANitaminMGPG/Mar18 Enquiries to Frances Adamson Extension: Direct Line: f.adamsonanhs.
NHS Grampian Westholme Woodend Hospital Queens Road ABERDEEN AB15 6LS NHS Grampian Date: 22nd March 2018 Our Ref: FANitaminMGPG/Mar18 Enquiries to Frances Adamson Extension: 56689 Direct Line: 01224 556689
More informationMEDICATION GUIDE ZUBSOLV (Zub-solve) (buprenorphine and naloxone) Sublingual Tablet (CIII)
MEDICATION GUIDE ZUBSOLV (Zub-solve) (buprenorphine and naloxone) Sublingual Tablet (CIII) IMPORTANT: Keep ZUBSOLV in a secure place away from children. If a child accidentally takes ZUBSOLV, this is a
More informationPeterborough Nalmefene Pathway Responsibilities for Specialist Services & GP
Peterborough Nalmefene Pathway Responsibilities for Specialist Services & GP INTRODUCTION/BACKGROUND In November 2014 NICE (National Institute of Clinical Excellence) published the Technology Appraisal
More informationTADPole: Treating Alcohol & other Drugs in Primary Care
Assessment The following are issues to consider in assessment. Drug use and treatment Quantity and pattern of use of all licit and illicit drugs Previous treatment and complications Dependence (tolerance,
More informationMEDICATION GUIDE SUBOXONE (Sub OX own) (buprenorphine and naloxone) Sublingual Film for sublingual or buccal administration (CIII)
MEDICATION GUIDE SUBOXONE (Sub OX own) (buprenorphine and naloxone) Sublingual Film for sublingual or buccal administration (CIII) IMPORTANT: Keep SUBOXONE in a secure place away from children. Accidental
More informationSECTION 9 : MANAGEMENT OF MOVEMENT DISORDERS AND EXTRAPYRAMIDAL SIDE EFFECTS
SECTION 9 : MANAGEMENT OF MOVEMENT DISORDERS AND EXTRAPYRAMIDAL SIDE EFFECTS Formulary and Prescribing Guidelines 9.1 Introduction Movement disorders and extrapyramidal side effects can manifest in the
More informationAnxiolytic, Sedative and Hypnotic Drugs. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Anxiolytic, Sedative and Hypnotic Drugs Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Anxiolytics: reduce anxiety Sedatives: decrease activity, calming
More information